Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
On January 24, 2025, Dr. Reddy’s Laboratories announced the filing of its unaudited condensed consolidated interim financial statements for the quarter ended December 31, 2024, with the United States Securities and Exchange Commission. This filing, submitted in Form 6-K, reflects the company’s adherence to international financial reporting standards and is available for public viewing on the SEC’s website. This update is crucial for stakeholders as it provides insights into the company’s financial health and performance during the specified quarter, potentially impacting investor decisions and market perceptions.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company based in Hyderabad, India. The company is primarily engaged in the development, manufacturing, and marketing of pharmaceutical products and active pharmaceutical ingredients. It serves markets worldwide, focusing on providing affordable and innovative medicines.
YTD Price Performance: -9.70%
Average Trading Volume: 1,485,577
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $12.44B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
